Project Grant R01AG103074
Award Date 9/1/26
Completion Date 5/31/31
Dollars Obligated $684K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
- The National Institute on Aging awarded the University of Washington $651,175 on February 1, 2026, under the Aging Research program (CFDA 93.866) to conduct a longitudinal follow-up study examining the relationship between female pubertal timing and biological aging. The research recruits female participants from the National Institute of Child Health and Human Development Study of Early Child Care and Youth Development (SECCYD), a landmark birth cohort. The study seeks to enroll approximately...
- The National Institute on Aging awarded the University of Delaware $1,303,632 on February 1, 2026, under the Aging Research program (CFDA 93.866) to examine sympathetic nervous system activation during the menopausal transition and its contribution to cardiovascular disease risk in women. The research addresses a gap in understanding physiological changes in cardiovascular function as follicle-stimulating hormone increases and estradiol declines across premenopausal, early perimenopausal, late...
- The National Institute on Aging awarded the University of Washington $777,500 on September 15, 2025, under the Aging Research program (CFDA 93.866) to conduct quantitative and qualitative research on interfacility transfers of older adults from emergency departments to other hospitals. The project will characterize outcomes and adverse events among transferred older adults using statewide administrative claims data, explore the experiences of older adults and care partners during transfer, and...
- The National Institute on Aging awarded Fred Hutchinson Cancer Center $3.35 million on August 15, 2026, under the Aging Research program (CFDA 93.866) to develop personalized guidance for menopausal hormone therapy decision-making. The project will create risk scores combining clinical, demographic, and genetic factors to provide individualized estimates of outcome risk with and without menopausal hormone therapy, addressing seven key MHT-associated outcomes: breast cancer, colorectal cancer,...
- The National Institute on Aging awarded New York University School of Medicine $3,557,115 on August 5, 2026, under the Aging Research program (CFDA 93.866) to investigate the neurobiological mechanisms linking menopause and cognitive decline in women. The recipient will conduct a longitudinal study mapping neurobiological changes during the menopause transition in a cohort of 120 pre- and perimenopausal women aged 40–48 using state-of-the-art neuroimaging, plasma proteomics, and clinical...
- The National Institute on Aging awarded Mayo Clinic $678,987 on August 5, 2026, under the Aging Research program (CFDA 93.866) to investigate the impact of menopause on blood pressure regulation during exercise. The research tests whether locomotor muscle afferent feedback and respiratory muscle work contribute to exaggerated blood pressure responses and impaired leg blood flow in post-menopausal women during submaximal exercise. The project has two specific aims: to determine if locomotor...
- The National Institute on Aging awarded Harvard Pilgrim Health Care, Inc. $706,310 on May 1, 2026, under the Aging Research program (CFDA 93.866) to conduct a longitudinal study examining the interplay among reproductive, molecular, and chronological age in relation to aging-related conditions in women. The study leverages existing high-quality data and biosamples from a well-phenotyped population of over 850 women followed from recruitment in early pregnancy in 1999–2002 for over two decades....
- The National Institute on Aging awarded the University of Washington $1,212,446 on September 1, 2026, under the Aging Research program (CFDA 93.866) to conduct longitudinal analysis of multi-omics biomarkers and their association with cognitive decline and dementia. The recipient will leverage serial multi-omics data with deep phenotyping to map mechanisms of cognitive decline and dementia and nominate druggable targets. The work uses two discovery and replication cohorts: the Cardiovascular...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded the University of Texas Medical Branch at Galveston $3.267 million on June 1, 2026, under the Aging Research program (CFDA 93.866). The research investigates the apolipoprotein E (APOE)-tau axis linking preeclampsia to Alzheimer's disease and related neurodegeneration. The project employs primary human trophoblast assays, pre-clinical humanized preeclampsia mouse models, and predictive and therapeutic...
- The National Institute on Aging awarded Rosalind Franklin University of Medicine & Science $696,253 on September 1, 2026, under the Aging Research program (CFDA 93.866) to investigate how hormonal fluctuations during perimenopause alter hippocampal neural circuits and accelerate Alzheimer's disease pathology in female mice. The recipient will use 4-vinylcyclohexene diepoxide (VCD) to chemically induce ovarian failure in AppNLGF knock-in AD model mice, mimicking human perimenopause...